Original article Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype

Cross sectional study of 57 consecutive HIV infected subjects taking protease inhibitortherapy for a median of 12.5 (1–29) months, seen in an outpatient HIV clinic. Controls were 17patients on non-nucleoside reverse transcriptor inhibitor therapy (NNRTI) for 9 (1–19) monthsand 50 antiviral naive patients.